Evidence map›Paper›PMID 35349649›Full record

SynthesisDiabetes care2022

Metabolomics and Type 2 Diabetes Risk: An Updated Systematic Review and Meta-analysis of Prospective Cohort Studies.

Jakub Morze, Clemens Wittenbecher, Lukas Schwingshackl, Anna Danielewicz, Andrzej Rynkiewicz, Frank B Hu, Marta Guasch-Ferré

Abstract readMeta-AnalysisSystematic Review
PubMed Full text at PMC Publisher
In one paragraph

Synthesis in Diabetes care, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 197 papers, 6 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
197citing papers in PubMed, 6 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

197 citing papers in PubMed, 6 syntheses or guidelines pooled it.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Pooled it
  6. Pooled it
  7. Trial
  8. Trial
  9. Trial
  10. Trial
  11. Trial
  12. Trial
  13. Trial
  14. Trial
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article

137 more citing papers are in PubMed but not listed here.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Jakub MorzeDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0002-7119-0273
Clemens WittenbecherDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0001-7792-877X
Lukas SchwingshacklInstitute for Evidence in Medicine, Medical Centre-University of Freiburg, Faculty of Medicine, University of Freiburg, Freiburg, Germany.
Anna DanielewiczDepartment of Human Nutrition, Faculty of Food Sciences, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Andrzej RynkiewiczDepartment of Cardiology and Internal Medicine, School of Medicine, University of Warmia and Mazury in Olsztyn, Olsztyn, Poland.
Frank B HuDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.
Marta Guasch-FerréDepartment of Nutrition, Harvard T.H. Chan School of Public Health, Boston, MA.ORCID 0000-0001-8525-1404

Funding

Transgenic CoreP30DK046200 · NIDDK · TUFTS MEDICAL CENTER · PI HU, FRANK B · 1992 to 2021
$25.0M
Circulating plasma metabolites, diet, and risk of type 2 diabetesR01DK112940 · NIDDK · BRIGHAM AND WOMEN'S HOSPITAL · PI HU, FRANK B, MORA, SAMIA · 2018 to 2021
$2.9M
Lifestyle Interventions, metabolites, microbiome, and diabetes riskR01DK127601 · NIDDK · HARVARD UNIVERSITY D/B/A HARVARD SCHOOL OF PUBLIC HEALTH · PI HU, FRANK B, RUIZ-CANELA, MIGUEL · 2021 to 2024
$1.9M
Circulating Plasma Metabolites, Lifestyle Factors, and Mortality RiskR21AG070375 · NIA · HARVARD SCHOOL OF PUBLIC HEALTH · PI GUASCH-FERRE, MARTA, SUN, QI · 2021 to 2022
$439k
NIA NIH HHS R21 AG070375NIDDK NIH HHS P30 DK046200NIDDK NIH HHS R01 DK112940NIDDK NIH HHS R01 DK127601
6 · The paper itself

Abstract

backgroundDue to the rapidly increasing availability of metabolomics data in prospective studies, an update of the meta evidence on metabolomics and type 2 diabetes risk is warranted. PURPOSE: To conduct an updated systematic review and meta-analysis of plasma, serum, and urine metabolite markers and incident type 2 diabetes. DATA SOURCES: We searched PubMed and Embase until 6 March 2021. STUDY SELECTION: We selected prospective observational studies where investigators used high-throughput techniques to investigate the relationship between plasma, serum, or urine metabolites and incident type 2 diabetes. DATA EXTRACTION: Baseline metabolites per-SD risk estimates and 95% CIs for incident type 2 diabetes were extracted from all eligible studies. DATA SYNTHESIS: A total of 61 reports with 71,196 participants and 11,771 type 2 diabetes cases/events were included in the updated review. Meta-analysis was performed for 412 metabolites, of which 123 were statistically significantly associated (false discovery rate-corrected P < 0.05) with type 2 diabetes risk. Higher plasma and serum levels of certain amino acids (branched-chain, aromatic, alanine, glutamate, lysine, and methionine), carbohydrates and energy-related metabolites (mannose, trehalose, and pyruvate), acylcarnitines (C4-DC, C4-OH, C5, C5-OH, and C8:1), the majority of glycerolipids (di- and triacylglycerols), (lyso)phosphatidylethanolamines, and ceramides included in meta-analysis were associated with higher risk of type 2 diabetes (hazard ratio 1.07-2.58). Higher levels of glycine, glutamine, betaine, indolepropionate, and (lyso)phosphatidylcholines were associated with lower type 2 diabetes risk (hazard ratio 0.69-0.90). LIMITATIONS: Substantial heterogeneity (I2 > 50%, τ2 > 0.1) was observed for some of the metabolites.

conclusionsSeveral plasma and serum metabolites, including amino acids, lipids, and carbohydrates, are associated with type 2 diabetes risk.

Indexed as

Diabetes Mellitus, Type 2Amino AcidsCarbohydratesHumansMetabolomicsObservational Studies as TopicProspective StudiesRisk FactorsAmino AcidsCarbohydrates

Identifiers

PMID35349649
PMCPMC9016744

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.